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Letter to the Editor
Is platelet gel safe enough for neutropenic patients?
Dear Editor,
Significant clinical advances have recently been made in the field of
regenerative medicine, involving the development of haemocompo-
nents for non-transfusional use. These products include: i) platelet-rich
plasma (PRP), ii) platelet-poor plasma (PPP), iii) platelet gel (PG), iv)
platelet-rich fibrin (PRF), v) serum eye drops (E-S) and vi) PRP eye
drops (E- PRP) [1,2]. All of these products are rich in growth factors
(VEGF, PDGF, TGF-β1 and other) and facilitate tissue regeneration in
vivo by potentiating the activity of resident mesenchymal stromal cells
[3]. PG has become very popular for the treatment of skin ulcers,
radiodermitis and other conditions [4–6]. Interestingly, Rebulla P et al
have demonstrated that PG can be obtained from cord blood. The use of
this substance has been proven to be very efficacious for tissue re-
generation [7]. In accordance with these findings, our group recently
described a case of life-threatening oral mucositis (OM) following high-
dose conditioning chemotherapy for peripheral blood stem cell trans-
plantation (PBSCT), which was successfully treated with cord blood
platelet gel (CBPG) [8]. Furthermore, Bonfili P and colleagues showed a
statistically significant improvement of OM with PG in patients treated
with chemo- and radio-therapy (RT) [9]. Chemotherapy consisted of 2
to 3 cycles of cisplatin (100 mg/m2) on days 1, 22 and 43 or weekly
intravenous cisplatin (40 mg/m2). RT was given according to a 3D-
model, ranging from 50 to 54 Gy in 25–27 fractions, up to 70 Gy to 35
fractions. These patients had some degree of neutropenia and OM at the
time when PG was administered. Neutropenia was defined as an ab-
solute neutrophil count (ANC) < 1.5 cells x 109/L, while severe neu-
tropenia as an ANC < 0.5 cells x 109/L or an ANC that is expected to
decrease < 0.5 cells x 109/L over the next 48 h [10]. Independently
from the degree of neutropenia, Bonfili P et al did not report any in-
fective complications in their study group. Thus, it is very unlikely that
PG serves as a pabulum for bacterial growth. Moreover, after local oral
treatment of OM, most of the PG would be either spitted out or swal-
lowed by patients.
In addition to these findings, PG displays clear anti-inflammatory
and analgesic properties [11–13] as well as anti-bacterial effects against
some microorganisms [3,7]. PG has strong efficacy in curing several
kinds of diabetic foot ulcers [14,15]. Moreover, PG is kept frozen (at
−80 °C) until use, thus minimizing any risk of bacterial contamination.
In summary, PG has so far proven to be efficacious in the treatment
of mucositis following chemo- and/or radiotherapy even in neutropenic
patients, without adding any additional infectious risk. Therefore,
randomized studies on the use of PG in neutropenic patients are now
indicated.
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